Laboratory-based and office-based Globorisk scores to predict 10-year risk of cardiovascular diseases among Iranians: results from the Fasa PERSIAN cohort

BMC Medical Research Methodology

Research

Dagfinn Aune¹  Azizallah Dehghan²  Mojtaba Farjam²  Fatemeh Rezaei³  Leila Jahangiry⁴ 

[1] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK;Department of Nutrition, Bjørknes University College, Oslo, Norway;Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran;Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran;Road Traffic Injury Research Center, Tabriz Health Services Management Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;Health Education and Health Promotion Department, School of Health, Medical Education Research Center, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran;

关键词: Laboratory-based;    Office-based;    Globorisk;    Cardiovascular disease;    Risk prediction;   

DOI  :  10.1186/s12874-022-01791-7

 received in 2022-04-10, accepted in 2022-11-11,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundGloborisk is a novel risk prediction model for predicting cardiovascular disease (CVD). Globorisk is a country-specific risk prediction model that determines CVD risk for all countries. This model has two versions; laboratory-based and office-based. This study aimed to determine the agreement between laboratory-based and office-based models in a large sample of the general population.MethodsBaseline data from the Fasa cohort study was used for the current study. In total, 6810 participants ≥ 40 years without any history of cardiovascular disease or stroke were included in the study. To determine the laboratory-based risk model, factors include age, sex, current smoking status, history of diabetes, systolic blood pressure (SBP), and total cholesterol. To estimate the office-based risk model, factors were age, sex, current smoking status, SBP, and body mass index (BMI). Kappa statistics was used to distinguish the agreement between grouped scores in these two models. Additionally, correlation coefficients and scatter plots were used to determine the linear correlation between the two models.ResultsIn this study 46.53% of the participants were men. The mean age (SD) of participants was 51.08 (7.88) years. Agreements between the two models were moderate and substantial in all women and all men, respectively. The agreement between the two CVD risk groups was 90.15% (kappa = 0.717) in all men, 92.94% (kappa = 0.571) among men aged < 60 years and 77.60% (kappa = 0.645) in men aged ≥ 60 years. The agreement between the two CVD risk groups was 86.68% (kappa = 0.572) among all women, 93.96% (kappa = 0.274) among women aged < 60 years and 62.46% (kappa = 0.422) among women aged ≥ 60 years. A very strong positive correlation (r = 0.94) was found between the two risk scores in all men, and it was similar among men aged < 60 years (r = 0.84) and men aged > 60 years (r = 0.94). Among all women, there was a very strong positive correlation (r = 0.87), and the strong positive correlation remained among < 60 years old (r = 0.76) and women > 60 years old (r = 0.76).ConclusionThe Globorisk office-based model which is easier to use as it does not require blood testing can determine the risk groups in this population. The Globorisk office-based model may be used for CVD risk screening in low-middle income countries where resources are limited.

【 授权许可】

CC BY   
© The Author(s) 2022. corrected publication 2022

【 图 表 】

Fig. 5

Fig. 2